scholarly journals The Key Differences between Human Papillomavirus-Positive and -Negative Head and Neck Cancers: Biological and Clinical Implications

Cancers ◽  
2021 ◽  
Vol 13 (20) ◽  
pp. 5206
Author(s):  
Steven F. Powell ◽  
Lexi Vu ◽  
William C. Spanos ◽  
Dohun Pyeon

Head and neck squamous cell carcinoma (HNSCC) is a unique malignancy associated with two distinct risk factors: exposure to typical carcinogens and infection of human papillomavirus (HPV). HPV encodes the potent oncoproteins E6 and E7, which bypass many important oncogenic processes and result in cancer development. In contrast, HPV-negative HNSCC is developed through multiple mutations in diverse oncogenic driver genes. While the risk factors associated with HPV-positive and HPV-negative HNSCCs are discrete, HNSCC patients still show highly complex molecular signatures, immune infiltrations, and treatment responses even within the same anatomical subtypes. Here, we summarize the current understanding of biological mechanisms, treatment approaches, and clinical outcomes in comparison between HPV-positive and -negative HNSCCs.

2009 ◽  
Vol 127 (1) ◽  
pp. 111-117 ◽  
Author(s):  
Elaine M. Smith ◽  
Michael Pawlita ◽  
Linda M. Rubenstein ◽  
Thomas H. Haugen ◽  
Eva Hamsikova ◽  
...  

2021 ◽  
Author(s):  
Haoru Dong ◽  
Xinhua Shu ◽  
Qiang Xu ◽  
Chen Zhu ◽  
Andreas M. Kaufmann ◽  
...  

AbstractHuman papillomavirus (HPV) infection identified as a definitive human carcinogen is increasingly being recognized for its role in carcinogenesis of human cancers. Up to 38%–80% of head and neck squamous cell carcinoma (HNSCC) in oropharyngeal location (OPSCC) and nearly all cervical cancers contain the HPV genome which is implicated in causing cancer through its oncoproteins E6 and E7. Given by the biologically distinct HPV-related OPSCC and a more favorable prognosis compared to HPV-negative tumors, clinical trials on de-escalation treatment strategies for these patients have been studied. It is therefore raised the questions for the patient stratification if treatment de-escalation is feasible. Moreover, understanding the crosstalk of HPV-mediated malignancy and immunity with clinical insights from the proportional response rate to immune checkpoint blockade treatments in patients with HNSCC is of importance to substantially improve the treatment efficacy. This review discusses the biology of HPV-related HNSCC as well as successful clinically findings with promising candidates in the pipeline for future directions. With the advent of various sequencing technologies, further biomolecules associated with HPV-related HNSCC progression are currently being identified to be used as potential biomarkers or targets for clinical decisions throughout the continuum of cancer care.


2020 ◽  
Vol 54 ◽  
pp. 93
Author(s):  
Daniela Herrera Posada ◽  
Lucia Stella Tamayo Acevedo ◽  
Marleny Valencia Arredondo ◽  
Gloria Inéz Sánchez Vásquez

OBJECTIVE: To estimate the prevalence of high-risk human papillomavirus (HR-HPV) anal infection and associated factors in human immunodeficiency virus (HIV) positive patients in Medellín. METHODS: Descriptive cross-sectional study in 300 HIV-positive patients, adults, with history of anal intercourse, treated in two health care services of Medellín 2017–2018. We conducted a structured survey on sociodemographics, sexual behavior and medical history. HPV was detected in anal swabs tested by the COBAS 4800 system. Exploratory data analysis of risk factors associated with HR-HPV was conducted by chi-square test of independence and both raw and adjusted prevalence ratios used the Poisson regression model, at a 95% confidence interval. RESULTS: The high-risk HPV had a prevalence of 82.7%; HPV16 had a prevalence of 32.7%, HPV18 a prevalence of 21.7% and other HPV types scored 78.3%. The high-risk HPV prevalence in women was of 68.2% and 83.8% in men. The risk factors associated with high-risk HPV after adjustment were age under 30 years, elementary education, casual sex partners, and first sexual activity before 18 years old. CONCLUSIONS: The high incidence of high-risk HPV, along with the occurrence of coinfections by multiple types in the study population shows their susceptibility to develop some type of anal intra-epithelial neoplasia. It is important to establish sexual health programs focused on primary health care.


1993 ◽  
Vol 138 (9) ◽  
pp. 735-745 ◽  
Author(s):  
Vesa Kataja ◽  
Stina Syrjänen ◽  
Merja Yliskoski ◽  
Maritta Hippeläinen ◽  
Martti Väyrynen ◽  
...  

2016 ◽  
Author(s):  
Rebecca L. Rohde ◽  
Nosayaba Osazuwa-Peters ◽  
Eric Adjei Boakye ◽  
Rajan Ganesh ◽  
Ammar Moiyadi ◽  
...  

Cells ◽  
2020 ◽  
Vol 9 (6) ◽  
pp. 1359 ◽  
Author(s):  
Chameera Ekanayake Weeramange ◽  
Kai Dun Tang ◽  
Sarju Vasani ◽  
Julian Langton-Lockton ◽  
Liz Kenny ◽  
...  

Disruption of DNA methylation patterns is one of the hallmarks of cancer. Similar to other cancer types, human papillomavirus (HPV)-driven head and neck cancer (HNC) also reveals alterations in its methylation profile. The intrinsic ability of HPV oncoproteins E6 and E7 to interfere with DNA methyltransferase activity contributes to these methylation changes. There are many genes that have been reported to be differentially methylated in HPV-driven HNC. Some of these genes are involved in major cellular pathways, indicating that DNA methylation, at least in certain instances, may contribute to the development and progression of HPV-driven HNC. Furthermore, the HPV genome itself becomes a target of the cellular DNA methylation machinery. Some of these methylation changes appearing in the viral long control region (LCR) may contribute to uncontrolled oncoprotein expression, leading to carcinogenesis. Consistent with these observations, demethylation therapy appears to have significant effects on HPV-driven HNC. This review article comprehensively summarizes DNA methylation changes and their diagnostic and therapeutic indications in HPV-driven HNC.


2006 ◽  
Vol 132 (8) ◽  
pp. 874
Author(s):  
M. Schultzel ◽  
G. Robins-Sadler ◽  
K. L. Clark ◽  
M. Loscalzo ◽  
R. Weisman ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document